Related Experiment Video
Updated: May 1, 2026
11:34
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
2.2K
Interaction between hepatitis C virus and metabolic factors.
Yasunori Kawaguchi1, Toshihiko Mizuta1
1Yasunori Kawaguchi, Toshihiko Mizuta, Department of Internal Medicine, Saga Medical School, Saga 849-8501, Japan.
World Journal of Gastroenterology
|March 25, 2014
Summary
Hepatitis C virus (HCV) infection causes insulin resistance and metabolic dysfunction. Lifestyle changes and certain medications can manage these issues, but some treatments should be avoided.
Area of Science:
- Hepatology
- Metabolic Disorders
- Virology
Background:
- Hepatitis C virus (HCV) infection significantly disrupts host metabolism, notably causing insulin resistance in hepatic and peripheral tissues.
- Cytokines like tumor necrosis factor-α contribute to HCV-induced insulin resistance, impacting distant tissues.
- HCV-related insulin resistance stems from oxidative stress, lipid abnormalities, hepatic steatosis, and iron overload.
Purpose of the Study:
- To elucidate the molecular mechanisms of HCV-induced insulin resistance.
- To characterize the effects of HCV-induced metabolic disturbances.
- To understand the interplay between HCV and host metabolic factors.
Main Methods:
- Review of existing research on HCV and metabolic pathways.
- Identification of contributing factors to insulin resistance in HCV infection.
- Analysis of clinical management strategies and their efficacy.
Main Results:
- HCV infection leads to glucose intolerance, impaired antiviral response, fibrosis progression, and reduced quality of life.
- Metabolic conditions like obesity and diabetes worsen HCV-associated metabolic disturbances and prognosis.
- Dietary recommendations include iron restriction, alcohol/tobacco abstinence, and increased green tea/coffee intake.
Conclusions:
- Metformin and statins show promise in managing metabolic disorders in HCV patients.
- Sulfonylurea and insulin therapies are not recommended for HCV-infected individuals with metabolic issues.
- Further research is needed to fully understand the molecular interactions between HCV and host metabolism.
Related Concept Videos
01:25Hepatitis
86
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
86
01:28Viral Hepatitis I: Introduction
25
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
25
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
382
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
382
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
271
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
01:16Hepatic Drug Excretion: Influencing Factors
818
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
818
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
358
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
358